Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Open Label ◽

Janus Kinase Inhibitor ◽

Phase Iii Studies

Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies

Revista Colombiana de Reumatología ◽

10.1016/j.rcreu.2018.08.002 ◽

2018 ◽

Vol 25 (4) ◽

pp. 233-244

Author(s):

Patricia Vélez ◽

Juan J. Jaller ◽

William J. Otero Escalante ◽

Erika G. García ◽

Ricardo Rojo ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Efficacy And Safety ◽

Janus Kinase Inhibitor ◽

Phase Iii Studies

Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies

Revista Colombiana de Reumatología (English Edition) ◽

10.1016/j.rcreue.2018.08.002 ◽

2018 ◽

Vol 25 (4) ◽

pp. 233-244

Author(s):

Patricia Vélez ◽

Juan J. Jaller ◽

William J. Otero Escalante ◽

Erika G. García ◽

Ricardo Rojo ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Efficacy And Safety ◽

Janus Kinase Inhibitor ◽

Phase Iii Studies

Efficacy and safety of topical janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis: Results of a phase IIA randomized clinical trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2012.12.823 ◽

2013 ◽

Vol 68 (4) ◽

pp. AB199

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Efficacy And Safety ◽

Faculty Opinions recommendation of A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717985064.793488596 ◽

2013 ◽

Author(s):

Kamran Ghoreschi

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Efficacy And Safety ◽

Faculty Opinions recommendation of A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717985064.793493020 ◽

2014 ◽

Author(s):

Benjamin Ehst

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Efficacy And Safety ◽

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

British Journal of Dermatology ◽

10.1111/bjd.14018 ◽

2015 ◽

Vol 173 (4) ◽

pp. 949-961 ◽

Cited By ~ 144

Author(s):

K.A. Papp ◽

M.A. Menter ◽

M. Abe ◽

B. Elewski ◽

S.R. Feldman ◽

...

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Janus Kinase Inhibitor ◽

Phase Iii Trials

OP0047 Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.252 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A65.2-A66 ◽

Cited By ~ 2

Author(s):

P. Taylor ◽

M. C. Genovese ◽

E. Keystone ◽

D. Schlichting ◽

S. Beattie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Extension Study ◽

Open Label ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

THU0197 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 8 years

10.1136/annrheumdis-2017-eular.1166 ◽

2017 ◽

Cited By ~ 4

Author(s):

J Wollenhaupt ◽

J Silverfield ◽

EB Lee ◽

K Terry ◽

K Kwok ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Open Label ◽

Janus Kinase Inhibitor ◽

Safety And Efficacy

704 Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000592352.44466.21 ◽

2019 ◽

Vol 114 (1) ◽

pp. S413-S414

Author(s):

Gary R. Lichtenstein ◽

Edward V. Loftus ◽

Arif Soonasra ◽

Nervin Lawendy ◽

Gary Chan ◽

...

Keyword(s):

Ulcerative Colitis ◽

Interim Analysis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Extension Study ◽

Open Label ◽

Corrigendum to "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.2020;82:823-31

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.07.010 ◽

2021 ◽

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽